Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Ameriprise Financial Inc. lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,539,247 shares of the company’s stock after selling 49,121 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.50% of Amneal Pharmaceuticals worth $12,191,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nantahala Capital Management LLC lifted its stake in Amneal Pharmaceuticals by 37.3% in the 4th quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company’s stock valued at $29,031,000 after purchasing an additional 995,586 shares during the last quarter. BlackBarn Capital Partners LP lifted its position in shares of Amneal Pharmaceuticals by 18.2% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company’s stock valued at $22,572,000 after buying an additional 438,388 shares during the last quarter. Mariner LLC lifted its position in shares of Amneal Pharmaceuticals by 3,749.1% in the fourth quarter. Mariner LLC now owns 424,291 shares of the company’s stock valued at $3,360,000 after buying an additional 413,268 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $2,946,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Amneal Pharmaceuticals by 5.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company’s stock worth $39,531,000 after acquiring an additional 278,653 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $7.60 on Monday. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -11.18 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.29 and a fifty-two week high of $9.48. The stock has a fifty day moving average price of $7.77 and a 200-day moving average price of $8.09.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares of the company’s stock, valued at $16,099,085.40. The trade was a 4.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AMRX has been the subject of several research reports. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $9.00 to $12.00 in a report on Monday, February 24th. Barclays upped their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $11.50.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.